Proof of concept studies for tissue-protective agents in multiple sclerosis

Abstract

Background

There is considerable interest in tissue-protective treatments for multiple sclerosis (MS).

Methods and Objectives

We convened a group of MS clinical trialists and related researchers to discuss designs for proof of concept studies utilizing currently available data and assessment methods.

Results

Our favored design was a randomized, double-blind, parallel-group study of active treatment versus placebo focusing on changes in brain volume from a post-baseline scan (3–6 months after starting treatment) to the final visit 1 year later. Study designs aimed at reducing residual deficits following acute exacerbations are less straightforward, depending greatly on the anticipated rapidity of treatment effect onset.

Conclusions

The next step would be to perform one or more studies of potential tissue-protective agents with these designs in mind, creating the longitudinal data necessary to refine endpoint selection, eligibility criteria, and sample size estimates for future trials.

Keywords

tissue protection clinical trial designs multiple sclerosis outcome measurement

Get full access to this article

View all access options for this article.

References

1 Karussis D Grigoriadis S Polyzoidou E Grigoriadis N Slavin S Abramsky O . Neuroprotection in multiple sclerosis. Clin Neurol Neurosurg 2006; 108: 250–254.

2 McFarland HF Reingold SC . The future of multiple sclerosis therapies: redesigning multiple sclerosis clinical trials in a new therapeutic era. Mult Scler 2005; 11: 669–676.

3 Rudick RA . Impact of disease-modifying therapies on brain and spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004; 14: 54S–64S.

4 Hardmeier M Wagenpfeil S Freitag P . European IFN-B1a in Relapsing MS Dose Comparison Trial Study Group. Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology 2005; 64: 236–240.

5 Hardmeier M Wagenpfeil S Freitag P . Atrophy is detectable within a 3-month period in untreated patients with active relapsing remitting multiple sclerosis. Arch Neurol 2003; 60: 1736–1739.

6 Gordon-Lipkin E Chodkowski B Reich DS . Retinal nerve fiber layer is associated with brain atrophy in multiple sclerosis. Neurology 2007; 69: 1603–1609.

7 Balcer LJ Baier ML Cohen JA . Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61: 1367–1373.

8 Baier ML Cutter GR Rudick RA . Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis. Neurology 2005; 64: 992–995.

9 Balcer LJ Galetta SL Calabresi PA . Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 2007; 68: 1299–1304.

10.

10 Anderson VM Bartlett JW Fox NC Fisniku L Miller DH . Detecting treatment effects on brain atrophy in relapsing remitting multiple sclerosis: sample size estimates. J Neurol 2007; 254: 1588–1594.

11.

11 Rudick RA Fisher E Lee JC Simon J Jacobs L . Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698–1704.

12.

12 Lublin FD Baier M Cutter G . Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003; 61: 1528–1532.

13.

13 Weinshenker BG O'Brien PC Petterson TM . A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–886.

14.

14 Filippi M Rovaris M Rocca MA . Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001; 57: 731–733.

15.

15 Dalton CM Miszkiel KA Barker GJ . Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251: 407–413.